Naproxen aggravates doxorubicin-induced cardiomyopathy in rats

Indian Journal of Pharmacology

Volumn 42, Issue 1, 2010, Pages 44-49

  Pathan, Rahila Ahmad ^a   Singh, Bhulan Kumar ^a   Pillai, K K ^a   Dubey, Kiran ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Apoptosis; Cardiomyopathy; Enzyme (kinetics); Free radicals; Nonsteroidal anti inflammatory drugs

Indexed keywords

CATALASE; DOXORUBICIN; GLUTATHIONE; LACTATE DEHYDROGENASE; NAPROXEN; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVITY; HEART; HEART PROTECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; TRANSMISSION ELECTRON MICROSCOPY;

EID: 77951682095     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.62411     Document Type: Article

References (35)

1. Bombardier C, Laine L, Reicin A. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000;343:1520-8.
2. Bresalier RS, Sandler RS, Quan H Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
3. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Arch Intern Med 2005;165:978-84.
4. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 2005;330:1366-70
5. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis Arch Intern Med 2002;162:1105-10.
6. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162:1111-5
7. Salpeter S, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L, et al. Meta-Analysis: Cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 2006;119:552-9.
8. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5.
9. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 1973;32:771-88.
10. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: The cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980;2:487-515.
11. Gosalvez M, van Rossuns GD, Blanco MF. Inhibition of sodium-potassium- activated adenosine 5′-triphosphatase and ion transport by adriamycin. Cancer Res 1979;39:257-61.
12. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987;19:817-28.
13. Olson RD, MacDonald JS, vanBoxtel CJ, Boerth RC, Harbison RD, Slonim AE et al. Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J Pharmacol Exp Ther 1980;215:450-4.
14. Inci I, Dutly A, Rousson V, Boehler A, Weder W. Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model. J Thorac Cardiovasc Surg 2001;122:1155-61.
15. Maridonneau-Parin I, Harpey C. Effect of trimetazidine on membrane damage nduced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985;20:148-51.
16. Perletti G, Monti E, Paracchini L, Piccinini F. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity. Arch Int Pharmacodyn Ther 1989;302:280-9.
17. Pascale C, Fornengo P, Epifani G, Bosio A, Giacometto F. Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects. LANCET 2002;359:1153-4.
18. Bergmeyer HU. Methods of enzymatic analysis. Vevlag chemie. 2nd ed. Weinheim London: Academic press; 1965. p. 574-9
19. Lum G, Gambino SR. A comparison of serum versus heparinised plasma for routine chemistry tests. Am J Clin Pathol 1974;61:108-13.
20. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8
21. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25:192-205
22. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7
23. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469-74
24. Clairborne A. Handbook of method of oxygen free radical research. Assay of catalase. In: Greenwald RA, editor. Boca Ratad, Florida: CRC Press; 1985. p. 283-4.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75
26. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14
27. Singal PK, Deally CM, Weinberg E. Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 1987;19:817-28.
28. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: Pathophysiology and prevention. FASEBJ 1997;11:931-6.
29. Malisza KL, Hasinoff B. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys 1995;321:51-60
30. Pascale C, Fornengo P, Epifani G, Bosio A, Giacometto F. Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects. Lancet 2002;359:1153-4.
31. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial nfarction in older adults. Circulation 2004;109:2068-73
32. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal antiinflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 2002;359:118-23.
33. Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005;365:475-81
34. Huang WF, Hsiao FY, Wen YW, Tsai YW. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (Celecoxib): A population-based analysis in taiwanese adults. Clin Ther 2006;28:1827-36.
35. Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: Does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 2007;46:435-8